<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04831437</url>
  </required_header>
  <id_info>
    <org_study_id>9711880002</org_study_id>
    <nct_id>NCT04831437</nct_id>
  </id_info>
  <brief_title>Clinical Response and Toxicity of Hypo-fractionated Chemoradiotherapy in Cervix Cancer</brief_title>
  <official_title>Comparison of Clinical Response and Toxicity of Hypo-fractionated Chemoradiation With Standard Treatment in Patients With Uterine Cervix Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Uterine cervix cancer can be treated definitively with concurrent chemoradiation (external&#xD;
      beam radiotherapy and chemotherapy) followed by high dose rate brachytherapy. Treatment&#xD;
      duration can be shortened by increasing the dose per fraction of treatment which can reduce&#xD;
      costs and patient exposure. The aim of our study is to determine the non-inferiority of&#xD;
      hypofractionated radiotherapy compared with conventional treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study we aim to determine if clinical response and toxicity of radiotherapy&#xD;
      hypofractionation is non-inferior to the conventional treatment. We will enroll 60 eligible&#xD;
      patients with cervical cancer stage IB to IIIC and randomly allocate them into the&#xD;
      intervention (hypofractionation) group or the control (standard) groups. The patients in the&#xD;
      intervention group will receive external beam radiotherapy(EBRT) to a total dose of 40 Gy in&#xD;
      15 fractions within 3 weeks concurrently with weekly chemotherapy with cisplatin 40mg/m2&#xD;
      (total of 3 cycles). Whereas, the control group will receive EBRT to a total dose of 45 Gy in&#xD;
      25 fractions within 5 weeks concurrently with weekly chemotherapy with cisplatin 40mg/m2&#xD;
      (total of 5 cycles). All patients from both groups will undergo high dose rate brachytherapy&#xD;
      one week after completion of EBRT to a total dose of 28 Gy per 4 weekly sessions. Patients&#xD;
      will be evaluated regarding early and late toxicities as described by Common Terminology&#xD;
      Criteria for Adverse Events (CTCAE) version 5.0 at the completion of brachytherapy, and at 3&#xD;
      months, 6 months, and 3 years from completion of treatment. Also, clinical response will be&#xD;
      evaluated through dynamic contrast enhanced pelvic MRI 3 months, 1 year, and 3 years after&#xD;
      completion of brachytherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">March 2028</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early toxicity</measure>
    <time_frame>3 months after completion of treatment</time_frame>
    <description>Early treatment-related toxicity within 3 months after completion of treatment as defined by CTCAE 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Early response</measure>
    <time_frame>3 months after completion of treatment</time_frame>
    <description>Early response to treatment at 3 months after treatment completion based on dynamic contrast-enhanced pelvic MRI findings</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late toxicity</measure>
    <time_frame>1 and 3 years after completion of treatment</time_frame>
    <description>Late treatment-related toxicity within 1 and 3 years after completion of treatment as defined by CTCAE 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Time from randomization to progression(based on MRI and physical examination), death, or last follow up; whichever that occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific survival</measure>
    <time_frame>5 years</time_frame>
    <description>Time from randomization to death from cervical cancer or last follow-up; whichever that occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Time from randomization to death from any reason or last follow-up; whichever that occurs first.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cervix Uteri Cancer</condition>
  <arm_group>
    <arm_group_label>Hypofractionated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EBRT 40Gy/15fr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EBRT 45Gy/ 25fr</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated EBRT</intervention_name>
    <description>EBRT dose of 40Gy in 15 fractions over 3 weeks plus 3 weekly infusions of cisplatin 40mg/m2</description>
    <arm_group_label>Hypofractionated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard EBRT</intervention_name>
    <description>EBRT dose of 45Gy in 25 fractions over 5 weeks plus 5 weekly infusions of cisplatin 40mg/m2</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathology of squamous cell carcinoma (SCC), adenocarcinoma, adenosquamous carcinoma of&#xD;
             uterine cervix- International Federation of Gynecology and Obstetrics (FIGO) stage IB,&#xD;
             IIA, IIB, IIIA, IIIB (due to hydronephrosis without creatinine clearance compromise),&#xD;
             IIIC1 (if less than 3 lymph nodes with size less than 3cm, and without involvement of&#xD;
             common iliac chain)- Patient eligible for definitive chemoradiotherapy followed by&#xD;
             brachytherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Creatinine clearance less than 30ml/min, any histology other than the above,&#xD;
             requirement of paraaortic lymph node irradiation, inflammatory bowel disease,&#xD;
             connective tissue disorders, previous pelvic radiotherapy, FIGO stage IA or IV,&#xD;
             Eastern Cooperative Oncology Group (ECOG) performance status greater than 2, History&#xD;
             of previous hysterectomy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Afsaneh Maddah-Safaei, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kasra Kolahdouzan, M.D.</last_name>
    <phone>+989144083785</phone>
    <email>k-kolahdouzan@razi.tums.ac.ir</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ebrahim Esmati, M.D.</last_name>
    <phone>+989126880306</phone>
    <email>eb_esmati@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Imam Khomeini Hospital Complex</name>
      <address>
        <city>Tehran</city>
        <zip>1419733141</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kasra Kolahdouzan, M.D.</last_name>
      <phone>+989144083785</phone>
      <email>k-kolahdouzan@razi.tums.ac.ir</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 2, 2021</study_first_submitted>
  <study_first_submitted_qc>April 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypofractionation</keyword>
  <keyword>Chemoradiation</keyword>
  <keyword>Brachytherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

